Practices
Industries
Jurisdictions

Lidings Strengthens Business Ties Between Russia and Iran

10 June 2025
Lidings successfully hosted a two-day visit by an Iranian business delegation on June 5–6, 2025, organized with the support of the Ferdowsi Legal dedicated to the markets of the Middle East countries. The event marked an important step in the development of economic and legal cooperation between Russia and Iran, opening new horizons for joint initiatives.

Lidings Creates Information Resource for Simplifying Cryptocurrency Accounting and Tax Reporting

31 March 2025
Starting from 2025, the Russian Tax Code includes regulations on cryptocurrency (digital currency) taxation. The Code provides an answer to one of the key questions - how to convert cryptocurrency value into rubles for accounting and tax calculation purposes. For this purpose, a market quotation mechanism has been introduced, applicable to corporate income tax (new Article 282.3 of the Tax Code) and personal income tax (revised clause 1 of Article 211 of the Tax Code).

Lidings - Appointed Exclusive Representative of WEX Crypto Exchange for Accepting Applications of Clients for Refunds – Informs on the Current Status of the Refund Procedure

26 March 2025

As previously communicated to WEX clients, the submission of applications and the compilation of client dossiers were suspended as of September 1, 2024. 

All applications submitted before this deadline have been processed, and the corresponding dossiers have been compiled and submitted to WEX’s management for review. We are pleased to report that significant progress has been made in locating clients, verifying their identities, and obtaining documentation confirming the lawful origin of their funds.

Lidings Team Wins a Precedent-Setting Dispute on The Cancellation of a Drug Registration Due to Inaccurate Information in The Drug Dossier

28 November 2024

Lidings’ Intellectual Property practice team succeeded in obtaining cancellation of registration of a drug in a dispute against the holder of the marketing authorisation (MA) due to the fact that during the process of registration of a generic drug product the Ministry of Health of Russia received false information from the holder of the MA.